| Literature DB >> 31556862 |
Ratnam S Seelan1, Robert M Greene1, Michele M Pisano1.
Abstract
The adverse developmental effects of exposure to Cigarette Smoke (CS) during pregnancy are documented in this paper. These include low birth weight, congenital anomalies, preterm birth, fetal mortality and morbidity. The current biological thought now recognizes that epigenetics represents a fundamental contributing process in embryogenesis, and that the environment can have a profound effect on shaping the epigenome. It has become increasingly recognized that genes encoding microRNAs (miRNAs) might be potential loci for congenital disabilities. One means by which CS can cause developmental anomalies may be through epigenetic mechanisms involving altered miRNA expression. While several studies have focused on genes affected by CS during embryonic/ fetal development, there is a paucity of knowledge on the involvement of miRNAs in this process. This brief review summarizes the current state of knowledge in this area. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: Cigarette smoke; e-cigarettes; embryonic development; epigenome; microRNAs; placenta.
Mesh:
Substances:
Year: 2020 PMID: 31556862 PMCID: PMC7365999 DOI: 10.2174/2211536608666190926114704
Source DB: PubMed Journal: Microrna
Summary of microRNAs affected by CS and implicated in development.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Mouse lung | - | miRNAs variably expressed in newborns, post-weanling females, and adult females. | Lung development affected | [ | |
| Mouse / human palate | Down-regulation implicated in cleft palate. | Cleft palate | [ | ||
| Human placenta | All 3 miRNAs down-regulated in CS-exposed tissues. | Altered fetal | [ | ||
| Human | 28 differentially expressed miRNAs in CS: 21 up-regulated (top); 7 down-regulated (bottom). | Transmission of harmful | [ | ||
| Human maternal and cord blood | - | High | Atopic dermatitis | [ |
*, validated targets; *1-5, numbers correlate miRNAs (in column 1) with their respective targets (in column 3);